Implementation of antithrombotic treatment in atrial fibrillation;Implementatie van antitrombotische behandeling bij atriumfibrilleren

Huisarts en Wetenschap

Volumn 54, Issue 4, 2011, Pages 192-196

  Willemsen, Robert ^a   Pisters, Ron ^b   Crijns, Harrie ^b   De Wit, Bram ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Huisartsenpraktijk Centrum   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; ARTICLE; DRUG DOSE REGIMEN; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; PRACTICE GUIDELINE; SCORING SYSTEM; STROKE; URBAN POPULATION;

EID: 79955147987     PISSN: 00187070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12445-011-0091-2     Document Type: Article

References (15)

1. Heeringa J, Van der Kuip DAM, Hofman A, Kors JA, Van Herpen C, Stricker BHC, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006;27:949-53.
2. Hohnloser SH, Pajitnev D, Pogue J, Healy JS, Pfeffer MA, Yusuf S, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007;50:2156-61. (Pubitemid 350123679)
3. Hart RC, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvulair atrial fibrillation. Ann Intern Med 2007;146:857-67. (Pubitemid 351650486)
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. Results from the national registry of atrial fibrillation. JAMA 2001;285:2864-70.
5. Lip G, Nieuwlaat R, Pisters R, Lane DA, Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010;137:263-72.
6. Cage BF, Van Walraven C, Pearce L, Hart RC, Koudstaal PJ, Boode BSP, et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
7. Boode BSP, Heeringa J, Konings KTS, Rutten FH, Van den Berg PJ, Zwietering PJ, et al. Nederlands Huisartsen Genootschap. Herziene NHG-Standaard atriumfibrilleren. Huisarts Wet 2009;52:646-63.
8. Opstelten W, Visscher S, Van Lieshout J. A chat about CHADS. Over de anti-trombotische behandeling bij atriumfibrilleren. Huisarts Wet 2009;-52:625.
9. Dinh T, Nieuwlaat R, Tieleman RC, Buller HR, Van Charante NA, Prins MH, et al. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in the Netherlands - the EXAMINE-AF study. A questionnaire survey. Int J Clin Pract 2007;61:24-31.
10. Nieuwlaat R, Capucci A, Camm J, Olsson B, Andresen D, Davies W, et al. Atrial fibrillation management: a prospective survey in ESC member countries. The Euro Heart Survey on atrial fibrillation. Eur Heart J 2005;26:2422-34.
11. Nieuwlaat R, Capucci A, Lipp G, Olsson B, Prins M, Nieman F, et al. Anti-thrombotic treatment in real-life atrial fibrillation patients. Eur Heart J 2006;27:3018-26.
12. Pisters R, De Vos CB, Nieuwlaat R, Crijns HJGM. Use and underuse of oral anticoagulation for stroke prevention in atrial fibrillation: old and new paradigms. Semin Thromb Hemost 2009;35:554-9.
13. Go AS, Hylek EM, Chang Y, Phillips K, Henault L, Capra A, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation. How well do randomized trials translate into clinical practice? JAMA 2003;290:2685-92.
14. Levi M, Hobbs FD, Jacobson AK, Pisters R, Prisco D, Bernardo A, et al. Improving antithrombotic management in patients with atrial fibrillation: current status and perspectives. Semin Thromb Hemost 2009;35:527-42.
15. Nieuwlaat R, Olsson B, Lipp G, Camm J, Breithardt G, Capucci A, et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. Am Heart J 2007;153:1006-12. (Pubitemid 46823965)